Nova Leap Health (NLH) Q4 2025 earnings summary

Executive summary

• Achieved record annual revenues, gross margin, and Adjusted EBITDA for 2025, with growth across both Canadian and U.S. segments.

• 2025 marked the strongest financial year in company history, driven by disciplined financial management and expansion.

Financial highlights

• 2025 revenues reached $31.5 million, up 22.2% year-over-year; Q4 2025 revenues were $8.1 million, up 22.8% from Q4 2024.

• Adjusted EBITDA for 2025 was $2,046,173, a 31.0% increase over 2024; Q4 2025 Adjusted EBITDA was $508,500, up 23.1% from Q4 2024.

• Gross profit margin improved to 39.7% in 2025 from 38.4% in 2024.

• Operating income for 2025 was $1,105,998, up 28.1% year-over-year.

• Q4 2025 net loss was $53,728, compared to net income of $426,171 in Q3 2025 and $886,268 in Q4 2024.

Outlook and guidance

• Management expects continued investment in organic growth and strategic acquisitions, supported by strong liquidity and low leverage.

• Forward-looking statements highlight plans for future expansion, cost savings, and growth in annualized revenue and Adjusted EBITDA margins.